Showing results (11-20 of 50) with videos related to
Sort By:
Pageof 5
Best Practice & Research. Clinical Gastroenterology|August 1, 2018
Can IL-23 be a good target for ulcerative colitis?Mariangela Allocca, Federica Furfaro, Gionata Fiorino, et al.Thescientificworldjournal|May 19, 2012
A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patientsStefano Ranno, Matteo Sacchi, Cinzia Brancato, et al.Current Pharmaceutical Design|March 9, 2019
Anti-fibrotic Drugs for Crohn's Disease: Ready for Prime Time?Marjorie Argollo, Daniela Gilardi, Giulia Roda, et al.European Journal of Gastroenterology & Hepatology|January 20, 2018
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in menMariangela Allocca, Daniela Gilardi, Gionata Fiorino, et al.Tumori|October 7, 2005
Urinary bladder metastases from breast carcinoma: review of the literature starting from a clinical caseGiovanna Gatti, Stefano Zurrida, Daniela Gilardi, et al.Expert Review of Clinical Immunology|January 10, 2017
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapyFederica Furfaro, Daniela Gilardi, Mariangela Allocca, et al.Current Drug Targets|May 28, 2016
Biologic Therapies in Ulcerative Colitis: Primi Inter Pares?Mariangela Allocca, Gionata Fiorino, Daniela Gilardi, et al.Current Drug Targets|March 22, 2019
Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient ProfileMarjorie Argollo, Paulo Gustavo Kotze, Laura Lamonaca, et al.The Lancet. Gastroenterology & Hepatology|June 8, 2019
Comorbidities in inflammatory bowel disease: a call for actionMarjorie Argollo, Daniela Gilardi, Carina Peyrin-Biroulet, et al.Expert Opinion on Biological Therapy|February 26, 2020
Modulation of sphingosine-1-phosphate in ulcerative colitisMarjorie Argollo, Federica Furfaro, Daniela Gilardi, et al.Pageof 5